page analyst certif import disclosur
technolog media telecommun thought capit one aw breach
servic profit end
publish juli
messag releas earn ahead estim post mid-teen y/i growth rev ebitda core basi strong
leas notabl includ multi-sit leas hyperscal support larg feder program believ compani
continu execut well support differenti sdp platform low cost basi asset well posit meet goal hyperscal
deal per year rais pt increas estim
page analyst certif import disclosur
publish juli
messag report top bottom line beat driven larg biktarvi letairi co also bump top line guidanc slightli
said focu call remain larg pipelin overal continu see valu base busi late stage
pipelin cash posit think recent event glpg sever smaller technolog in-licens deal sign build momentum behind
busi develop bd engin maintain buy rais pt
publish juli
messag result posit revenu ep beat payment volum forecast underli oper
momentum appear strong manag updat impli sequenti improv bottom line rais revenue/ep estim
think continu demonstr solid oper perform acquisit like transfast support continu solid volume/
revenu growth risk/reward look balanc view share signific ytd ralli vs think
multipl look stretch across space howev pt increas roll forward remain buy rate
publish juli
messag post modest beat estim guidanc rais primarili incorpor wavecel acquisit
execut improv new channel market leadership appear settl nearli two year chang revenu
growth remain large-arr deal channel contribut point healthier trajectori quarter ahead rise tide
environ caa bode well peer group think multipl expand acceler growth rate quarter ahead
maintain neutral rate rais price target improv outlook
page analyst certif import disclosur
publish juli
messag paycom deliv strong y/i revenu growth y/i ebitda growth beat street estim
revenu ebitda also rais revenu ebitda guidanc rel consensu continu improv
unusu combin growth profit valuat top hcm coverag see limit upsid level
rais price target higher estim
 doubl stuf rais maintain buy
publish juli
messag mondelez deliv remark strong result beat alreadi lofti growth expect manag rais sale ep
growth guidanc year continu like degre flexibl algorithm strong momentum high likelihood
continu upward revis maintain ep estim rais ep due stronger sale
growth year off-set least partial higher interest tax rais price target due primarili higher earn
result recap thought follow bam jv
publish juli
messag result strong fdc also report solid result quarter note termin coverag fdc /fdc
deal close yesterday thought post-today confer call announc fdc/baml separ bottom line see limit financi
impact separ forecast time period addit note earn call manag indic
combin fisv/fdc could eventu exceed initi revenu synergi target increas pro-forma ep rais
pt roll forward remain buy-rat
page analyst certif import disclosur
 buy second take slight chang guid cloud
publish juli
messag solid metric led revenu beat overshadow reduct ebitda guidanc lower
ebitda guid reflect slightli higher cost relat new deliveri market onboard new enterpris restaur relationship
disappoint lower outlook appear directli relat competit loyalti program perk roll nation mid august
market support fall could improv dag trend
sr maintain sight sound lt growth higher
publish juli
messag sr report consensu estim mo rate design chang continu main driver y/i variat one last
quarter despit pipelin delay end calendar higher cost estim final manag rais capital-expenditure outlook
reiter confid lt earn growth firmli found regul organ growth coupl contribut ga storag
market busi solid fundament sr busi support construct view compani remain neutral rate
valuat leav us wait attract entri point
buy earn drive narrow jakafi guidanc
pivot vitiligo studi design confirm pt
publish juli
messag report earn see preview includ top bottom line estim beat well rais lower
end jakafi guidanc previous pipelin catalyst remain track includ initi pivot
topic ruxolitinib program vitiligo final trial design confirm today call rais pt reiter
buy rate given convict sustain jakafi growth approv indic addit upsid potenti topic ruxolitinib derm
opportun frontlin gvhd opportun itacitinib
page analyst certif import disclosur
 review rais secur acceler
publish juli
messag post anoth beat rais quarter out-performance media carrier web divis segment
media traffic greater expect segment benefit uptak compani secur product believ gain
momentum enterpris custom larg total address market opportun howev maintain neutral rate given current
market valuat approach pt
 setup second half
publish juli
messag deliv nice beat revenu ebitda result rais guidanc year
leav room potenti headwind interest rate cut win larger custom continu roll compani shift focu up-
market year ago proport custom live two year reach base good mileston margin improv
tweak estim second half leav larg unchang reiter buy rate price target share
rl readi knight stock
publish juli
messag rl report result includ better-than-expect sales/oper expens leverag drive adj ep beat
vs overal continu believ rl remain strong lifestyl brand play across categories/maintain global recognit led
experienc leadership team encourag sever initi solid perform intern europe/asia continu
invest elev brand/stabil north america continu believ share fairli valu reiter neutral-r await
sign sustain top-lin growth particularli north america amid uncertain geopolit environ
page analyst certif import disclosur
 work done
publish juli
messag morn report result revenu came expect grow vs estimate apparel
na wholesal segment busi declin lsd gross margin expand vs estimate adjust ly
restructur impact sg dollar grew less anticip part due time shift aid bottom line encourag
progress key initi remain neutral larg due valuat earli day plan introduc dec
await visibl strong healthi growth competit global activewear market
celg neutral revenu beat across portfolio drive rais
guidanc transact track
publish juli
messag celg report revenu beat across major commerci product result increas total revenu guidanc
well increas product-level guidanc pomalyst abraxan pipelin notabl includ key asset ozanimod luspatercept
liso-cel fedratinib remain track management confirm continu expect bmy/celg transact close end
begin given pend transact remain neutral
go set-up attract fundament remain neutral
publish juli
messag context potenti choppi report season retail space believ go set-up august print attract
expect seem reason especi top-lin perspect manag like set initi guidanc bar essenti line
current consensu would includ sale ebitda growth respect latter encompass step-up
public compani cost despit compel fundament stay neutral-r valuat see exhibit share trade
adjust ebitda
page analyst certif import disclosur
 busi mix continu shift regul
without surpris bump
publish juli
messag post slight miss overal mix disclosur pse power weaker power outlook surpris
previous mark commod stick point remain pse polici align nj clean energi infrastructur settlement
outcom narrow pse rate base growth wait datapoint opportun associ nj energi master
remain construct reiter buy pt
crsp model updat data later year i/o
move clinic
publish juli
messag key updat came crsp report yesterday compani announc crsp/vrtx plan
present initi b-thal scd data late think like first b-thal pt treat transfusion-fre post tx scd pt
treat i/o side thing studi allo car-t open crsp end cash
opex although see signific potenti crsp highli innov platform diversifi approach think potenti reflect
current level maintain neutral rate
 feedback industri convers
publish juli
messag launch coverag alteryx earlier month follow increment feedback name base
convers variou industri particip spoken numer peopl past week custom industri analyst privat
compani present unvarnish feedback note feedback mostli posit ayx product data prep analyt
long runway growth also heard concern mid- long-term concern competit data prep space
also potenti risk aw azur analytics/ml space
page analyst certif import disclosur
 growth mix drift cost reiter buy
publish juli
messag post good quarter revenu new pet subscript beat expect full year revenu guidanc increas
well said soft metric includ lvp/pac ratio veterinari invoic percent sale miss expect suggest cost
also grow ultim expect veterinari invoic number drift necessarili see uncharacterist reiter
buy rate base solid growth prospect strong moat under-penetr industri reiter buy pt
bgne buy meet management highlight upcom zanubrutinib
publish juli
messag host lunch meet bgne cfo chief strategi offic howard liang senior director ir craig west
convers manag highlight potenti area differenti zanubrutinib btk inhibitor detail around design
upcom phase trial waldenstrom macroglobulinemia wm overview zanubrutinib clinic program cll follicular lymphoma
fl updat thought develop opportun tislelizumab
 neutral read-though addl valid
kra competit bar may rise
publish juli
messag announc earn includ posit updat kra inhibitor potenti competitor
provid addit clinic updat world confer lung cancer abstract releas
european societi medic oncolog meet see esmo planner note impress note new clinic respons colorect
appendic cancer patient drug seem less activ see posit news serv strong addl extern
valid view also potenti rais competit bar compound data guid
page analyst certif import disclosur
neg comment vogtl re-baselin report
staff often surpris
publish juli
messag ga psc staff today file comment regard vogtl re-baselin report rais doubt project in-servic date
see potenti cost increas assum in-servic staff comment cast gener neg tone surpris
statement consid past viewpoint subject view major sourc concern look increment data
point progress vogtl call tomorrow
lex deal like break-even ep
publish juli
messag complet acquisit liberti expedia class lexea class lexeb lex collect last week
highlight issu share lex held share oper busi net debt share count come
consolid bodybuild com loss redeem debt chairman barri diller vote power goe
right get back buy share market swap super vote share acquir lex see deal
modest posit clean control structur thesi changer
 vumer demonstr improv gi toler tecfidera
publish juli
messag spoke follow today posit top-line data phase trial head-to-head comparison look gi
toler vumer diroximel fumar tecfidera dimethyl fumar rm takeaway vumer superior tecfidera
primari endpoint number day gi event overal ae discontinu vs gi-rel discontinu vs
rate better vumer vs tecfidera view data support biib strategi direct new patient either switch drug
rm vumer tecfidera potenti life-extens strategi ms franchis
page analyst certif import disclosur
 first look weaker result due uk headwind
publish juli
messag report top bottom line result expect miss primarili driven uk busi saw
signific pressur new volum brexit use margin vehicl over-suppli impact result retail commerci truck
ptl perform remain strong segment grow profit double-digit gross margin miss forecast primarili due use vehicl
weak uk sg gross profit deleverag expect along quarterli result announc acquisit
warner truck center commerci truck retail dealership billion annual revenu
publish juli
messag mrk report strong sale y/i estimate ep y/i better
consensu est respect driven keytruda gardasil pediatr vaccin growth especi china solid overal
qualiti lower-than-expect sg bp absolut basi result varianc tabl attach
publish juli
messag lli sale ep beat our/consensu estim
respect better-than-expect sale incom estim strike tax benefit bp
expect two item drove adjust ep comparison see tabl report
thought capit one aw breach
publish juli
messag capit one yesterday report secur breach sinc one largest breach aws/cloud rais question cloud
secur vulner exploit could prevent fact alleg attack ex-aw employe play
role attempt answer question note also believ bring focu need appropri secur control cloud
could help rais awar cloud secur tool redlock chkp
page analyst certif import disclosur
model updat news expect stream servic profit end
publish juli
cb morri dive updat cb subscript revenu trend tradit digit subscrib follow announc renew agreement
altic usa
highlight shift wireless manag note open sever avenu fund work other
plan evolv
shop wong maintain neutral rate investor sentiment remain posit focus new opportun though note potenti drag
margin
amladi rais price target clean beat-and-rais revenu track underpin durabl compani
gutman maintain neutral rate despit strong result rais fy guidanc current strong market valuat manag
expect near-term impact s/tmu merger
gutman highlight first look result includ strong revenu ebitda growth includ multi-sit leas
mccormack rais pt updat model includ postpaid subscrib estim
mccormack detail updat model chang includ lower video commerci revenu increas video subscrib loss
vs prior increas mobil net add rais ebitda estim
publish juli
guggenheim host client util event includ annual
tx power ga wire bu tour es dinner eei meetings/util
dinner ndr schedul among event scroll
sante cooper move forward potenti sale/restructur process
ni settlement reach class action lawsuit merrimack valley incid
ma/offshor wind vineyard wind need get nod nation marin fisheri servic
legal settlement clear path southern reliabl link
seek cost recoveri cancel nuclear project municip cooper custom
page analyst certif import disclosur
ale/lnt/wec il mi attorney gener oppos atc transmiss project wi
ap issu two rfp renew
wife late john mccain pen op- support ap ceo brandt
ed/ne mvp addit varianc request submit ferc weekli report issu develop ferc review
ed juli outag root caus identifi ceconi
fdc termin coverag
publish juli
termin coverag first data corpor fdc due acquisit compani inc
lexea termin coverag
publish juli
termin coverag liberti expedia lexea due acquisit
page analyst certif import disclosur
inc
primari analyst jake fuller
page analyst certif import disclosur
primari analyst glen santangelo
page analyst certif import disclosur
